Skip to main content
OpenTrials
Completed

NCT Number: NCT07261800

Sex-specific Differences in the Association Between Leg Fat and Diabetes Risk

This study investigates the association between LFP, VAT and T2DM using DXA in 542 adults. We apply penalized regression, generalized additive models (GAM), and causal mediation analysis to explore whether higher LFP reduces diabetes risk and whether this effect is mediated by VAT. Sex-specific analyses further clarify the biological differences in adipose distribution. The findings aim to improve understanding of fat distribution and metabolic health.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Shandong First Medical University

Jinan, China

About this study

T2DM is a major public health concern, and growing evidence suggests that not all body fat confers equal metabolic risk. Beyond total adiposity, the regional distribution of fat strongly influences insulin resistance and diabetes development. VAT is metabolically detrimental, promoting inflammation and lipotoxicity, whereas lower-body subcutaneous fat, particularly in the legs and gluteofemoral region, may exert protective metabolic effects by serving as a "safe storage" depot for excess lipids. However, the causal mechanisms underlying these associations remain incompletely understood, and whether the protective role of LFP differs by sex remains unclear.

This study aims to elucidate the metabolic and causal pathways linking LFP, VAT, and diabetes risk in adults. Using DXA for precise body composition assessment, the study evaluates the associations between LFP, VAT, and T2DM prevalence, with a focus on sex-specific effects. A total of 542 adult participants will be analyzed, including both men and women with and without T2DM. Clinical, biochemical, and anthropometric data will be collected concurrently.

The analytic framework integrates multiple complementary approaches:

  • Penalized regression models (LASSO, ridge, elastic net) will identify the most predictive adiposity components for T2DM while minimizing collinearity.
  • GAMs will examine potential nonlinear relationships between LFP, VAT, and diabetes risk, separately for male and female.
  • Causal mediation analysis will quantify the extent to which VAT mediates the relationship between LFP and diabetes, providing mechanistic insight into adipose redistribution pathways.
  • Inverse-probability-of-treatment weighting (IPTW) will strengthen causal inference by balancing covariates across LFP strata.
  • Two-sample Mendelian randomization (MR) will further test the causal effect of genetically predicted LFP on T2DM risk using summary-level genome-wide association data.

We hypothesize that higher LFP will be associated with lower diabetes risk and that this protective effect will be partially mediated by reduced VAT accumulation, particularly in females.

This study integrates imaging-based body composition, causal modeling, and genetic validation to bridge observational and causal evidence. The findings are expected to improve the understanding of sex-specific fat distribution in metabolic health and support the development of personalized prevention strategies targeting regional adiposity rather than total body fat.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults (≥18 years old)

Available DXA measurement of fat distribution

Complete fasting glucose or diabetes diagnosis record

Exclusion criteria

  • Missing key variables (fat distribution, diabetes status)

Severe systemic disease interfering with data integrity

Implausible or inconsistent records

Treatment and study plan

Not Applicable - Retrospective study

Other

Not Applicable - Retrospective study

Primary outcomes

  1. Prevalence of diabetes in relation to lower extremity fat

    Time frame: Baseline

    T2DM will be defined according to standard diagnostic criteria (fasting plasma glucose ≥ 7.0 mmol/L and/or HbA1c ≥ 6.5%, or a physician diagnosis). The primary outcome is the association between LFP and diabetes status, estimated using multivariable logistic regression and causal mediation analysis.

Secondary outcomes

  1. Mediating Effect of VAT

    Time frame: baseline

    Quantification of the indirect effect of VAT in the association between LFP and T2DM risk, estimated via causal mediation analysis.

  2. Sex-specific Differences in the LFP-T2D Association

    Time frame: Baseline

    Evaluation of whether the association between LFP and diabetes risk differs between males and females using sex-stratified models and interaction testing.

Other outcomes

  1. Nonlinear Relationship Between LFP/VAT and T2D Risk (GAM Analysis)

    Time frame: baseline

    Characterization of potential nonlinear (threshold or saturation) relationships between LFP, VAT, and diabetes risk using generalized additive models (GAMs).

  2. Causal Association Between Genetically Predicted LFP and T2D (Mendelian Randomization)

    Time frame: baseline

    Two-sample Mendelian randomization (MR) using genome-wide association study (GWAS) summary statistics to test the causal effect of genetically predicted LFP on T2D risk.

Sponsors and collaborators

Lead sponsor

Qianfoshan Hospital

Other

Registry information

Official study title

Sex-specific Differences in the Association Between Leg Fat and Diabetes Risk: The Mediating Role of Visceral Adipose Tissue

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Dec 3, 2025
Registry last updated
Dec 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.